ERBB2 and breast cancer: Recently, Wu H. et al. performed immunohistochemistry to investigate the expression level of TMEM16A and Ki67 (a well-known marker for cell proliferation) in 403 BC patients, and investigated whether the expression level of TMEM16A linked to Ki67 in BC subtypes classified by ER, PR, and HER2(Wu et al., 2017).